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Abstract
Mobilization of the GLUT4 glucose transporter from intracellular storage vesicles provides a mechanism for insulin-
responsive glucose import into skeletal muscle. In humans, clathrin isoform CHC22 participates in formation of the GLUT4
storage compartment in skeletal muscle and fat. CHC22 function is limited to retrograde endosomal sorting and is restricted
in its tissue expression and species distribution compared to the conserved CHC17 isoform that mediates endocytosis and
several other membrane traffic pathways. Previously, we noted that CHC22 was expressed at elevated levels in regenerating
rat muscle. Here we investigate whether the GLUT4 pathway in which CHC22 participates could play a role in muscle
regeneration in humans and we test this possibility using CHC22-transgenic mice, which do not normally express CHC22.
We observed that GLUT4 expression is elevated in parallel with that of CHC22 in regenerating skeletal muscle fibers from
patients with inflammatory and other myopathies. Regenerating human myofibers displayed concurrent increases in
expression of VAMP2, another regulator of GLUT4 transport. Regenerating fibers from wild-type mouse skeletal muscle
injected with cardiotoxin also showed increased levels of GLUT4 and VAMP2. We previously demonstrated that transgenic
mice expressing CHC22 in their muscle over-sequester GLUT4 and VAMP2 and have defective GLUT4 trafficking leading to
diabetic symptoms. In this study, we find that muscle regeneration rates in CHC22 mice were delayed compared to wild-
type mice, and myoblasts isolated from these mice did not proliferate in response to glucose. Additionally, CHC22-
expressing mouse muscle displayed a fiber type switch from oxidative to glycolytic, similar to that observed in type 2
diabetic patients. These observations implicate the pathway for GLUT4 transport in regeneration of both human and mouse
skeletal muscle, and demonstrate a role for this pathway in maintenance of muscle fiber type. Extrapolating these findings,
CHC22 and GLUT4 can be considered markers of muscle regeneration in humans.
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Introduction
The recently-characterized isoform of clathrin in humans,
known as CHC22, plays a specific role in sorting the GLUT4
glucose transporter to an insulin-responsive intracellular compart-
ment in skeletal muscle and fat [1]. Insulin-stimulated release of
GLUT4 from this GLUT4 storage compartment (GSC) to the
plasma membrane enables glucose uptake by these tissues in which
GLUT4 is preferentially expressed, constituting the major
pathway of post-prandial glucose clearance from human blood
[2–6]. Prior to definition of its specific function in GSC formation,
our studies of CHC22 showed elevated levels in rat muscle
undergoing regeneration after cardiotoxin injury [7]. Indepen-
dently, other elements of the GLUT4 glucose uptake pathway
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have been implicated in rat muscle regeneration. Following
cardiotoxin injury of rat muscle, GLUT4 expression is enhanced
in regenerating fibers [8], as is expression of the vesicle-associated
membrane protein-2 (VAMP2, also known as synaptobrevin),
which mediates fusion of GLUT4-containing vesicles with the
plasma membrane upon release from the GSC [9,10]. VAMP2
expression is also enhanced in rat satellite cells [11], the muscle-
associated cells that mediate regeneration of adult skeletal muscle
[12]. These coincidental findings suggested that the GLUT4
glucose import pathway controlled by CHC22 might play a role in
muscle regeneration. Here we address this hypothesis through
analysis of regenerating human muscle tissue and muscle
regeneration in transgenic mice expressing CHC22, two systems
in which the CHC22-GLUT4 interaction can be more readily
studied than rat muscle due to species restrictions of available
antibody and genetic tools.
Skeletal muscle regeneration occurs continuously to repair
muscle damage incurred during normal activity and is enhanced
in response to disease or injury [12]. When regeneration cannot
compensate for disease-induced deterioration, dystrophies and
other chronic myopathies ensue. During adult regenerative
myogenesis, satellite cells, which are normally quiescent, are
stimulated by injury to proliferate, differentiate and fuse with one
another or with existing myofibers to restore normal tissue
architecture. Specialized membrane traffic plays a role in the
development and maintenance of skeletal muscle function [13].
However, the membrane trafficking pathways involved in skeletal
muscle regeneration are relatively uncharacterized.
Here, we address a role in skeletal muscle regeneration for
CHC22, a second clathrin heavy chain isoform encoded on
human chromosome 22. In contrast to the ubiquitous form of
clathrin (CHC17 isoform), which is responsible for receptor-
mediated endocytosis and sorting in the trans-Golgi network,
CHC22 mediates a specific step in membrane traffic during
retrograde endosomal sorting and does not operate in endocytosis
[14]. CHC22 is present at low levels in many cell types, but its
expression is highest in skeletal muscle, where retrograde
endosomal sorting contributes to sequestration of GLUT4 in the
GSC. In fact, CHC22 expression increases upon differentiation of
myoblasts and adipocytes [1,15] as they begin to express GLUT4
and form an insulin-responsive GSC, suggesting that CHC22 is a
key player in the GLUT4 pathway. Notably, however, the murine
gene encoding CHC22 clathrin evolved into a pseudogene, though
it is present in other vertebrates [16]. Consequently, mice lack
CHC22 and instead form their insulin-responsive GSC using
transport pathways mediated by CHC17 [17]. Another membrane
traffic protein absent from mice that operates in the same
retrograde transport pathway, syntaxin 10 [18], is also required for
human GSC formation [14]. When expressed as a transgene
encoded by its human tissue-specific promoter in mouse muscle
and fat, CHC22 causes aberrant localization of GLUT4 and
VAMP2 and formation of an expanded GSC with impaired
function [1]. Thus, CHC22 is needed for functional trafficking of
both GLUT4 and VAMP2 to the GSC in human tissue, but its
presence in mouse tissue disrupts trafficking pathways that
normally proceed in its absence, conferring diabetic symptoms
on the CHC22-mice [1].
Our early studies of CHC22 analyzed rat muscle by immuno-
fluorescent labeling with an antibody against CHC22 and detected
an increase in CHC22 immunostaining upon regeneration after
cardiotoxin injection [7]. However, apart from microscopy
evidence, we were not able to isolate CHC22 protein from rats,
possibly due to weak cross-reactivity of antibodies recognizing
human CHC22. To circumvent this problem and clarify a
potential role for CHC22 and GLUT4 membrane traffic in
muscle regeneration in the present study, we analyzed GSC
pathway markers in human muscle sections from patients with
four different myopathies including inflammatory myopathies,
which are characterized by abundant regenerating myofibers [19].
Regenerating human myofibers showed elevated levels of CHC22,
GLUT4 and VAMP2 compared to mature fibers and we observed
elevated GLUT4 and VAMP2 in regenerating mouse myofibers.
Furthermore, we found that the perturbation of GLUT4 and
VAMP2 traffic in muscle of mice expressing CHC22 as a
transgene was associated with impairment of muscle regeneration
following cardiotoxin injection and with a change in muscle fiber
type. Finally, we observed that cultured myoblasts from CHC22
trangenic mice could fuse into myotubes but did not proliferate in
response to glucose, which stimulated wild-type myoblast prolif-
eration. Together these observations identify a functional GLUT4
transport pathway as a component of skeletal muscle regeneration
and myogenesis in both humans and mice.
Materials and Methods
Ethics Statement
Human muscle samples from patients with polymyositis,
dermatomyositis, limb girdle muscular dystrophy, necrotizing
myopathy and from control subjects were from the neuropathol-
ogy archives of the University of Tsukuba and UCSF. For the
samples from Tsukuba, the patient identity was coded to protect
patient confidentiality. The study was approved by the Ethics
Committee of University of Tsukuba Hospital and we confirm that
written informed consent was obtained from patients for the use of
their tissue in research. For the samples from UCSF, the study
design was approved by the UCSF Committee on Human
Research and the informed consent requirement was waived
based on the non-invasive nature of the study and a minimal
potential for harm to study participants. For animal experiments,
all procedures were conducted in accordance with UCSF and
National Institutes of Health guidelines, as approved by the UCSF
Institutional Animal Care and Use Committee.
Antibodies
Monoclonal and polyclonal antibodies against CHC22 have
been described [1,15]. Mouse anti-VAMP2 antibody was from
Synaptic Systems (Goettingen, Germany). Rabbit polyclonal anti-
GLUT4 was a gift from Jeffrey Pessin (Albert Einstein College of
Medicine, Bronx) and mouse monoclonal anti-IRAP was a gift
from Morris Birnbaum (University of Pennsylvania). Goat
polyclonal anti-GLUT4 was from Santa Cruz (Santa Cruz, CA)
and mouse monoclonal anti-GLUT4 was from Sigma (St. Louis,
MO). Mouse monoclonal antibody against embryonic myosin
heavy chain (F1.652) was from the Developmental Studies
Hybridoma Bank, University of Iowa. Mouse monoclonal
antibody against Pax7 (1G11) was from Sigma. Antibodies against
Type I (clone NOQ7.5.4.D/MAB1628) and Type II (clone MY32)
myosin heavy chains were from Millipore, MA and Abcam,
Cambridge, UK respectively. Antibodies to CHC17 clathrin
(monoclonal X22 against the heavy chain and polyclonal against
the light chain subunits) were produced in the Brodsky laboratory
and their characterization published previously [20,21].
Human Tissue and Quantification
To identify UCSF cases for the study, we performed a
computerized search of the UCSF neuropathology case database
using terms ‘‘dermatomyositis’’ and ‘‘necrotizing myopathy’’,
spanning the interval between 2007 and 2013. Three muscle
CHC22 on Muscle Regeneration
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biopsies were chosen for each disease category based on (1)
absence of unusual pathologic or clinical features, (2) availability
and quality of frozen muscle tissue, and (3) abundance of
regenerating muscle fibers observed in hematoxylin and eosin-
stained cryosections (Figure S1). The Tsukuba cases were selected
in a similar fashion. The Tsukuba University neuropathology case
database for 2000–2005 was searched manually for terms
‘‘polymyositis’’, ‘‘dermatomyositis’’ and ‘‘limb girdle muscular
dystrophy’’, and muscle biopsies were chosen for each disease
category. Muscle biopsy tissue of patients without final clinical or
histological evidence of a myopathy served as normal controls.
In Figures 1 and 2, total fluorescence intensity per fiber was
calculated using Image J as follows: Total = (integrated pixel values
per fiber) – (area of fiber 6 mean background fluorescence).
Adjusted total was determined to compare samples from different
patients and was calculated by setting the average total fluores-
cence value of the eMHC2 fibers for each patient to the arbitrary
number of 100, then total fluorescence of the eMHC+ fibers in
each patient was adjusted by the same factor used to set the
eMHC2 fibers to 100. For quantification of internal fluorescence
intensity for each fiber, a line was drawn around the fiber
boundary (dotted line in magnified panels of Figure 1) and a
second line was drawn 2.5 microns from this in the direction of the
interior of the fiber (line formed by arrowheads pointing to the
interior in magnified panels of Figure 1). The integrated
fluorescent signal inside the interior line was divided by the
integrated fluorescence signal inside the exterior line to calculate
the percent internal intensity. For the quantification in Figure 1G,
five random fields from each patient section (n=4 for PM and
n=3 for DM) were scored for the presence of eMHC and intense
internal CHC22 staining (approximately 800–1300 total fibers per
patient).
For the quantification in Figure 3, sections from patients
diagnosed with dermatomyositis (n=3) or necrotizing myopathy
(n=3) were analyzed. For each patient, 10 to 17 different fields
were acquired and total, Pax7+, Pax7+CHC22+, Pax7+GLUT4+
and Pax7+CHC22+GLUT4+ cells were counted. Results were
expressed as proportion of total or Pax7+ cells with approximately
500–1500 cells per patient scored.
Cardiotoxin Injection
0.1 ml of 10 mM cardiotoxin (Sigma, St. Louis, MO) in 0.9%
saline was injected directly into the right TA muscle and 0.1 ml of
0.9% saline was injected into left TA muscle with a 27-gauge
needle under isoflurane anesthesia. The needle was inserted into
TA muscle longitudinally from ankle to knee and was held in place
for a few seconds, then slowly withdrawn along the long axis of the
TA muscle with a little pressure to allow permeation of the
cardiotoxin throughout the muscle. On day 1, 3, 5, 7, 14, 20, 28,
and 56 after injection, six mice were sacrificed with an
intraperitoneal injection of ketamine/medetomidine followed by
cervical dislocation, and the cardiotoxin-injected TA muscles
(right) and saline-injected contralateral TA muscles (left) were
removed for analysis. The muscles from three mice per time point
were frozen in isopentane cooled by liquid nitrogen for histological
analysis. Histological analysis was performed quantitatively as
described after standard hematoxylin and eosin (H & E) staining.
The cross-sectional area and diameter of regenerating muscle
fibers with central nuclei (5006150) in three sections from each
mouse (three mice for each time point) were measured using
Image J 1.38x, then, mean cross-sectional area or diameter was
calculated for each time point. The muscles from the three
additional mice per time point were frozen directly in liquid
nitrogen for protein expression analysis and stored at 280uC.
Mice used for these experiments were 8 weeks of age.
Immunoblot Analysis
For lysates prepared from freshly isolated mouse skeletal muscle,
tissue was homogenized with a polytron (3 times 5 s, speed 5) in
lysis buffer (1 g/7 ml 50 mM Tris-HCl pH 7.5, 0.15 M NaCl,
1 mM EDTA, 1% NP40 and 1 protease inhibitor cocktail tablet
(1/10 ml buffer, Roche)). Homogenate was centrifuged (10 min,
14,0006g) and the pellet discarded. Protein concentration of the
lysate was determined by Bradford assay (Biorad). Lysates of
human myoblast cultures were prepared as described [14]. Protein
samples were separated by electrophoresis (10% acrylamide gel),
then electrophoretically transferred to nitrocellulose (Millipore,
Billerica, MA). The presence of CHC22 or other proteins in
samples was assayed by immunoblotting, using a chemilumines-
cent reagent (Western Lightning Chemiluminescence Reagent
Plus; PerkinElmer Life Sciences, Waltham, MA). Secondary
antibodies were conjugated to horseradish peroxidase (Jackson
ImmunoResearch Laboratories, West Grove, PA). Quantification
was performed using Quantity One software (Biorad, Hercules,
CA).
Immunolabeling
Human skeletal muscle biopsy samples were embedded in
Tissue-Tek OCT compound (Miles Inc., Elkhart, IN), frozen, and
stored at 280uC (Tsukuba samples) or mounted using tragacanth
gum, frozen in isopentane cooled by liquid nitrogen, and stored at
280uC (UCSF samples). Cryosections (5–10 mm thick) were
collected on microscope slides, fixed for 10 min with 4%
paraformaldehyde in PBS at room temperature and then washed
twice (10 min each) with PBS at 4uC. After a 5-min permeabiliza-
tion with 0.5% Triton X-100 in PBS at room temperature and a
30-min saturation with PBS supplemented with 0.1% Triton X-
100, 0.5% bovine serum albumin, the sections were incubated
overnight at 4uC with the primary antibodies in PBS supplement-
ed with 0.1% Triton X-100, 0.5% bovine serum albumin, and 2%
goat serum and washed three times (10 min each) at 4uC with PBS
and 0.1% Triton X-100. The sections were then incubated with
secondary antibodies for 30 min at room temperature. After three
10-min washes in PBS and 0.1% Triton X-100 at room
temperature, the nuclei were stained with DAPI, and the samples
were mounted with an anti-fading solution (DABCO). For double
labeling, the two primary antibodies (from different species) and
the two secondary antibodies were added at the same time. The
secondary antibodies were labeled with either Alexa-488, Alexa-
568 (both from Molecular Probes, Carlsbad, CA), or Cy3 (Jackson
ImmunoResearch Laboratories, West Grove, PA). Images of
muscle sections were acquired by confocal laser scanning
microscopy (Nikon EZ-CiSi operating system and Leica DM1
6000 CS, SP5). Alexa-488, Alexa-568, or Cy3 fluorescence was
sequentially excited and collected (400 Hz line by line) by using a
488-nm argon laser line for Alexa-488 and a 561-nm helium-neon
laser line for Alexa-568 and Cy3 excitation. Fluorescence emission
was collected from 493 to 555 nm for Alexa-488 and from 566 to
630 nm for Alexa-568 and Cy3. Part of the data for this study
were acquired at the Nikon Imaging Center at the Mission Bay
campus of UCSF.
Transgenic Mice
Generation of the CHC22 transgenic mice is detailed elsewhere
[1].
CHC22 on Muscle Regeneration
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Figure 1. Increased internal CHC22 in regenerating muscle fibers in several human myopathies. A, B, C and D) Transverse sections of
human skeletal muscle from a control individual or patients with polymyositis (PM), dermatomyositis (DM) or limb girdle muscular dystrophy (LGMD)
were immunostained with polyclonal antibody against CHC22 (red) and a monoclonal antibody against embryonic myosin heavy chain (eMHC,
green). Black and white images for each antibody are shown. In the merged color images nuclei were stained with DAPI (blue) and red-green overlap
is shown in yellow (scale bars, 20 mm). The boxed regions in the merged images are magnified seven-fold at the far right and show CHC22 staining
only. To illustrate the way in which internal fiber staining was quantified, the fiber boundaries drawn are shown in the magnified boxed regions with
the thin dashed line representing the fiber border and the line of arrowheads representing the boundary for quantifying internal staining with the
arrowheads pointing to the fiber interior. Only a segment of the fiber quantified is shown, but the asterisks in the internal region highlight the
CHC22 on Muscle Regeneration
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Human Myotube Culture
LHCNM2 human skeletal muscle cells were a gift from W.
Wright, University of Texas Southwestern Medical Center
[1,14,24]. Cells were grown on rat-tail collagen coated flasks in
basal media (4:1 DMEM:M199, 20 mM M HEPES, 0.03 mg/l
ZnSO4, 1.4 mg/l Vitamin B12) supplemented with 10% FBS,
55 mg/l dexamethasone, 2.5 ng/ml HGF, 50 mg/ml penicillin,
50 mg/ml streptomycin and 0.625 mg/l fungizone (growth media).
Differentiation was achieved by switching media to early
differentiation media on day 0 (basal media supplemented with
0.5% FBS, 10 mg/l insulin, 50 mg/l apo-transferrin and 5.5 mg/l
dexamethasone) and later differentiation media (basal media
supplemented with 0.5% FBS, 10 mg/l insulin, 50 mg/l apo-
transferrin and 55 mg/l dexamethasone). Later differentiation
media was used as soon as multinucleated myotubes appeared in
the culture, normally after about 7 days. Cells were differentiated
for an additional 7 days. TNF-a (10 ng/ml), IL-1b (50 pg/ml) and
IFN-c (50 ng/ml) were included in the cultures as described in the
text and the legend to Figure 4.
NADH-tetrazolium Reductase (NADH-TR) Staining of
Mouse Muscle Sections
Transverse sections from snap-frozen muscle samples, day 28
after injury, were stained for myofiber type [22]. Fibers were
identified as red, intermediate or white by setting fixed parameters
for all the sections and cross-sectional area was determined for
each fiber, using ImageJ. Tissue sections were scored blind and
sections from three CHC22-mice or three WT mice were scored,
representing an approximate total of 1500 fibers from each mouse
type.
Mouse Primary Myoblast Culture
Primary myoblasts were derived from the hind limb muscles of
WT and CHC22-transgenic mice [23]. To induce differentiation
and fusion, myoblasts were seeded at a density of 26105 cells/well
on dishes coated with entactin, collagen IV and laminin (E-C-L;
Upstate Biotechnology) in growth media [GM: DME, 10% FBS,
10 mM HEPES, 50 mg/ml penicillin, and 50 mg/ml streptomy-
cin], then switched to fusion media [FM: DME, 1% insulin-
transferrin-selenium-A supplement (Invitrogen)], 100 U/ml peni-
cillin G and 100 mg/ml streptomycin) with low (5.6 mM) or high
(25 mM) glucose. At indicated time points after the switch to FM,
cells were immunostained by peroxidase using antibody against
eMHC (F1.652; Developmental Studies Hybridoma Bank) and
analyzed as described [24]. At least 800 nuclei were analyzed for
each culture condition and myoblasts from three independent
isolations from both CHC22 and WT mice were assayed.
Statistical Analysis
Statistical significance between two groups or among multiple
groups was evaluated using Student’s t test, Fisher’s exact test,
Tukey-Kramer’s test after the F-test, or one-way or two-way
analysis of variance (ANOVA) by Microsoft Excel, Graphpad,
Prism or js-STAR2012 (ver.2.00j). For each figure, the test used is
specified in the legend.
Results
CHC22 and Components of the GLUT4 Compartment are
Increased and Co-localized in Regenerating Human
Muscle
Detection of elevated levels of CHC22 in recovering injured rat
muscle suggested that pathways involving CHC22 could be
involved in regeneration [7]. To explore this possibility for human
tissue, CHC22 expression was analyzed in skeletal muscle sections
from patients with several different myopathies. The idiopathic
inflammatory myopathies polymyositis (PM, n = 4) and dermato-
myositis (DM, n = 3) were chosen for analysis because they are
characterized by muscle tissue with high levels of inflammation
and an active regeneration response [19]. Sections from patients
with limb girdle muscular dystrophy (LGMD, n=3) were also
examined to study a non-inflammatory muscle myopathy.
LGMDs are autosomal muscular dystrophies encompassing a
large number of rare disorders with a common phenotype of adult-
onset with slowly progressive weakness involving shoulder or
pelvic-girdle muscles [25]. The LGMD patients in our study,
although not having been diagnosed with specific genetic defects,
had a family history of affected siblings and were positive for
dystrophin immunostaining, distinguishing them from the more
common form of muscular dystrophy, X-linked Duchenne’s
muscular dystrophy. In patients’ tissue, regenerating myofibers
were identified by immunostaining for embryonic myosin heavy
chain (eMHC) and central nuclei [26], commonly used markers
for skeletal muscle regeneration (Figure 1). Compared to mature
eMHC-negative myofibers, regenerating eMHC-positive myofi-
bers in sections of all three myopathies displayed more intense
CHC22 immunostaining. This CHC22 staining was primarily in
intracellular structures and localized in the interior of the fiber
(Figures 1A–F). In contrast, CHC22 immunostaining in mature
fibers and in the control sample was mainly concentrated at the
plasma membrane. For the three patient tissues shown in
Figures 1B–D, quantitative analysis of fiber staining (in several
fields) revealed that eMHC-positive fibers had significantly more
intense total CHC22 staining and increased internal staining
(Figures 1E and 1F), compared to eMHC-negative fibers from the
same patients. When muscle samples from three DM patients and
four PM patients were analyzed for double labeling of eMHC and
CHC22, the frequency of intense internal CHC22 immunostain-
ing was significantly higher in eMHC-positive muscle fibers than
in eMHC-negative myofibers (about 65–70% vs 10–20%,
Figure 1G).
increased internal staining in the eMHC-positive fibers compared to the control. E) Quantification of total CHC22 fluorescence intensity (adjusted for
patient comparison, see methods) in eMHC-negative (eMHC2) fibers (n= 40) from all patients and eMHC-positive (eMHC+) fibers from patients with
PM (n= 17), DM (n=14) or LGMD (n=5) in the patients shown in A–D, where n is the number of fibers analyzed for each patient. All patients had
statistically significant higher CHC22 fluorescence intensity in eMHC+ fibers (solid grey bars) compared to eMHC2 fibers (solid black bar), as
determined by one-way ANOVA (*p,0.05, **p,0.01, ***p,0.001). F) Quantification of internal CHC22 (internal pixel values/total pixel values with
internal staining cut-off 2.5 microns beneath the fiber border, as illustrated in A–D in eMHC-negative (eMHC2) fibers (n= 19) from all patients and
eMHC2positive (eMHC+) fibers from patients with PM (n= 8), DM (n=4) or LGMD (n=3) in the patients shown in A–D, where n is the number of
fibers analyzed for each patient. Internal CHC22 fluorescence was significantly higher in eMHC+ fibers from patients with PM, DM and LGMD as
determined by one-way ANOVA (*p,0.05, **p,0.01, ***p,0.001). G) The frequency of muscle fibers with internal CHC22 labeling was determined for
fibers that were eMHC+ with central nuclei or eMHC2 fibers in muscle sections from patients with PM (n= 4) and DM (n=3), immunostained as in A,
where n is the number of patients analyzed. All patients analyzed had a statistically significant higher frequency of internal CHC22 in eMHC+ fibers
(solid bars) than in eMHC2 fibers (open bars) (**p,0.01), as determined by Fisher’s exact test.
doi:10.1371/journal.pone.0077787.g001
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Figure 2. Co-localization of CHC22 and components of the GLUT4 trafficking pathway in regenerating human muscle. A, B and C)
Transverse sections of skeletal muscle from a patient with PM were immunostained with a polyclonal antibody against GLUT4 (red) and monoclonal
antibodies against A) embryonic myosin heavy chain (eMHC, green), B) CHC22 (green) or C) CHC17 (green). Regenerating myofibers were identified
by centrally located nuclei stained with DAPI (blue in merge). Boxed regions in the merged images are magnified seven-fold at the right showing
overlap of markers in yellow (scale bars, 20 mm). D and E) Transverse sections of skeletal muscle from a patient with PM were immunostained with a
polyclonal antibody against CHC22 (red) and a monoclonal antibody against VAMP2 (green). Regenerating myofibers were identified by centrally
CHC22 on Muscle Regeneration
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The role of CHC22 in GLUT4 trafficking pathways in human
myoblasts and adipocytes prompted a comparison of CHC22 and
GLUT4 expression in regenerating human skeletal muscle. In
sections from patients with PM, regenerating myofibers that were
labeled for eMHC also displayed intense GLUT4 immunostaining
with an interior distribution similar to that of CHC22 (Figure 2A,
magnified box) and the two proteins were partially co-localized
(Figure 2B, magnified box). Quantification of additional myofibers
from the sections shown in Figure 2A and 2B confirmed increased
internal GLUT4 in fibers that were eMHC-positive or positive for
internal CHC22. Ubiquitous CHC17 clathrin was not more
prominent in myofibers with high levels of GLUT4 compared to
other fibers throughout the muscle sections examined and,
although quantification suggested some increase along with
GLUT4, this was not statistically significant (Figure 2C, magnified
box). The differential expression pattern of CHC22 and CHC17 is
consistent with the clear delineation of function of these two
clathrins in human skeletal muscle [1,14]. The observation that
both CHC22 and GLUT4 staining is shifted internally in
regenerating myofibers is consistent with the established perinu-
clear localization of GLUT4-containing intracellular compart-
ments, since nuclei in regenerating muscle are more centrally
located, while mature fibers are characterized by sub-sarcolemmal
nuclei (26).
Following up the implication of an amplified GLUT4 transport
pathway in regenerating fibers, sections from the same patients
were immunolabeled to localize VAMP2. In small regenerating
myofibers identified by central nuclei [26] and high levels of
intracellular CHC22, VAMP2 immunostaining was intense
throughout the cytoplasm and co-localized extensively with
located nuclei stained with DAPI (blue in merge). Boxed regions in the merged images are magnified seven-fold at the right showing intracellular co-
localization (yellow) of CHC22 and VAMP2 in a regenerating fiber of D) small diameter or E) large diameter (scale bars, 20 mm). At the far right, the
percent internal staining for the markers indicated on the y-axis was quantified as in Figure 1F, for fibers that were characterized according to internal
staining for the marker indicated on the x-axis. n is the number of fibers analyzed in each staining combination shown at the left. Significant
increased internal staining was determined by Student’s t-test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0077787.g002
Figure 3. CHC22 and GLUT4 in satellite cells expressing Pax7. A) Transverse sections of human skeletal muscle from patients diagnosed with
dermatomyositis (DM) or necrotizing myopathy (NM) were immunostained with a monoclonal antibody against Pax7, a polyclonal (rabbit) antibody
against CHC22 and a polyclonal (goat) antibody against GLUT4. Arrowheads indicate Pax7+ CHC22+ GLUT4+ cells. (scale bars, 50 mm) B) The
frequency of Pax7-positive cells with increased CHC22 and/or GLUT4 labeling was quantified for sections from DM (n= 3) and NM (n= 3) patient
samples, immunostained as in A.
doi:10.1371/journal.pone.0077787.g003
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CHC22 (Figure 2D, magnified box). In larger regenerating
myofibers with elevated levels of intracellular CHC22, VAMP2
co-localization with CHC22 was also clearly observed (Figure 2E,
magnified box). Both proteins displayed punctate immunostaining
(Figures 2D and 2E, magnified boxes) and quantification
confirmed a significant increase in internal VAMP2 in fibers that
were positive for internal CHC22. Enhanced expression of
VAMP2 has been described for regenerating rat myofibers [11],
and the observations here demonstrate that this is also a
characteristic of human regenerating myofibers. Thus three
components of the GLUT4 trafficking machinery, CHC22,
GLUT4 and VAMP2, were all elevated in the interior of human
regenerating myofibers.
The presence of CHC22 and GLUT4 in regenerating fibers
defined by expression of eMHC and central nuclei raised the
question of whether satellite cells participating in regeneration also
express CHC22 and GLUT4. We therefore characterized
distribution of these proteins compared to the satellite cell marker
Pax7 [27], analyzing muscle tissue from two more sets of patients,
comprising a new cohort of DM patients (n=3), as well as patients
with necrotizing myopathy (NM, n=3). NM is characterized by
the presence of necrotic and regenerating fibers in the absence of
significant inflammation. For Pax7 expression analysis, the DM
and NM patient samples were selected for a high content of
regenerating fibers, visible upon H & E staining, and we confirmed
that these samples had abundant fibers that co-stained for
intracellular CHC22 and GLUT4 (Figure S1). The selected
samples were then triple-labeled for Pax7, CHC22 and GLUT4
(Figure 3). Pax7-positive cells were observed associated with the
rims of myofibers in both disease states (Figure 3A). In DM, almost
100% of Pax7-positive cells displayed strong labeling for both
CHC22 and GLUT4 and for NM .80% of Pax7-positive cells
showed intense labeling for all three markers (Figure 3A arrow-
heads and Figure 3B). Together these human tissue studies suggest
a link between CHC22 and its associated GLUT4 pathway in the
muscle regeneration process. They further suggest that CHC22
could be a reliable marker for regenerating fibers in human
muscle.
Inflammatory Cytokines Present in Damaged Muscle do
not Affect CHC22 Expression
Tumor necrosis factor (TNF)-a, a multi-functional cytokine, is
elevated in muscle of patients with PM, DM and Duchenne’s
muscular dystrophy, and expression of TNF-a correlates with
levels of muscle regeneration [28]. TNF-a signaling through NF-
kB and p38MAPK has been shown to increase the translocation of
GLUT4 vesicles to the plasma membrane in rat L6 muscle cells
[29]. Given this connection between TNF-a, muscle regeneration
and glucose metabolism, we investigated whether expression of
TNF-a might be responsible for the elevated levels of CHC22 and
GLUT4 in regenerating myofibers. To address this, we added
TNF-a to differentiating human myoblast cultures and assessed
expression levels of CHC22 and GLUT4. For comparison, the
effects of other inflammatory cytokines, interleukin 1b (IL-1b) and
interferon gamma (IFN-c), were also analyzed. IL-1b is also
increased in muscle of patients with inflammatory myopathies,
while levels of IFN-c are not particularly elevated [19]. Exogenous
cytokines were added to human myoblasts (LHCNM2 cells)
[1,14,30] either on day 1 of switching to differentiation media or
on day 9 of differentiation and cells cultured further, collecting
samples for analysis on progressive days of differentiation
(Figure 4). As we previously observed, CHC22 levels increased
during days 1–9 of differentiation [15]. TNF-a and IFN-c had the
expected effect of strongly increasing expression of class I
histocompatibility molecules (Class-I), evaluated as a positive
control (Figure 4A) [31–33]. However, levels of CHC22, CHC17
and GLUT4 expressed in the presence of each cytokine were
comparable to control levels of expression at each time point
(Figure 4). These culture experiments suggest the dramatic
increase observed for CHC22 and GLUT4 immunofluorescence
in regenerating fibers is not a response to inflammatory cytokines,
consistent with the fact that increase of both markers was also
observed in the non-inflammatory human myopathies (LGMD
and NM). We hypothesize that these observed increases reflect a
role for upregulation of the GLUT4 pathway that is intrinsic to
muscle regeneration.
Figure 4. Effect of cytokines on human myoblast or myotube cultures. A) LHCNM2 human skeletal muscle myoblasts were cultured under
differentiation conditions for the indicated number of days in the presence or absence (2) of the indicated cytokines. Cell lysates prepared on the
indicated day were analyzed by immunoblotting for the protein indicated at the left. B) Experiment as in A with addition of indicated cytokines on
differentiation day 8 when myotubes had formed. Molecular mass (kilodaltons) of the proteins detected is indicated at the right.
doi:10.1371/journal.pone.0077787.g004
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Levels of GLUT4 Pathway Components Increase in
Regenerating Muscle from Wild-type and Transgenic
Mice
The gene encoding CHC22 is a pseudogene in mice, a property
shared by sixteen strains of wild mice, as well as laboratory mice
[16]. In mouse muscle, the GSC is formed in the absence of
CHC22, relying on CHC17-mediated transport [17,34]. Trans-
genic mice that express CHC22 under the control of its
endogenous human promoter have been produced and charac-
terized (CHC22-mice). In these mice, CHC22 protein was
detected in muscle and adipose tissue, and not in other tissues
by immunoblotting [1]. Upon further histological analysis (data
not shown), CHC22 was also detected in a subset of cerebellar
neurons but not motor neurons, consistent with the presence of the
GLUT4 pathway in some cerebellar neurons [35]. We previously
showed that, in CHC22-mice, the presence of CHC22 in muscle
traps GLUT4 in an intracellular compartment, resulting in less
GLUT4 on the muscle cell surface under ad lib feeding conditions
[1]. To determine whether CHC22 expression in the transgenic
mice parallels that observed for human regenerating muscle fibers,
muscle degeneration and regeneration were induced by injection
of cardiotoxin into the tibialis anterior (TA) muscle. This insult
causes extensive and reproducible muscle necrotic injury and the
regeneration program that ensues is well documented [36]. After
cardiotoxin injection, satellite cell proliferation occurs within two
days, myogenic differentiation is initiated within three days, new
myofiber formation is evident within five days, and muscle
architecture is largely restored within ten days [36]. In
cardiotoxin-treated TA muscle from CHC22-mice, expression of
CHC22 increased upon muscle regeneration, as assessed by
quantification of immunoblotting experiments (Figure 5A). Thus
factors regulating CHC22 expression in regenerating human
muscle are also present in regenerating mouse muscle and can
stimulate the human CHC22 promoter.
To determine whether other components of the GLUT4
pathway were increased during mouse muscle regeneration, the
expression levels of VAMP2 (Figure 5A) and GLUT4 (Figure 5B)
were also analyzed. In WT mice, VAMP2 levels increased
dramatically, starting on day 5 after injection, peaking at day 7,
and decreasing afterwards. In regenerating muscle of CHC22-
mice, there was an apparent delay in the increase of VAMP2
expression, and elevated VAMP2 persisted longer during the
regeneration period compared to WT mice (Figure 5A). Our
previous studies indicated increased stability of VAMP2 in
untreated muscle of CHC22-mice [1]. This might explain the
observed change in VAMP2 behavior in the presence of CHC22
because the changes in VAMP2 level correlated with changes in
CHC22 level (Figure 5A). This observation is consistent with the
expanded and partially defective GSC in the CHC22-mice that we
described previously [1]. For the CHC22-mice, increased expres-
sion of GLUT4 was observed during muscle regeneration with no
significant differences from the expression pattern seen for WT
mice (Figure 5B). For both WT and CHC22-mice, GLUT4 levels
were down on days 3 and 5, after toxin injection caused necrosis.
GLUT4 levels then increased as regeneration proceeded, peaking
on day 14, but remaining at levels higher than those observed one
day post-injury, even at day 28, unlike the dramatic drop in
VAMP2. The increase in components of the GLUT4 pathway in
wild-type and CHC22-mice parallels that observed for rat [7] and
human (Figures 1–3) regenerating muscle. Notably, in the
CHC22-mice, CHC22 expression behaves as a component of
the GLUT4 pathway. However, because of the CHC22 expres-
sion, GLUT4 transport is impaired in their skeletal muscle [1], so
the CHC22-mice can be analyzed to assess whether GLUT4
traffic contributes to muscle regeneration.
Delayed Maturation of Regenerating Fibers in Mice
Expressing CHC22
To determine whether muscle regeneration is affected in the
CHC22-mice, the cross-sectional area and the diameter of
regenerated myofibers, were analyzed over a time course following
injury by cardiotoxin, as it is documented that these parameters
increase progressively as regeneration occurs. Regenerating
myofibers were also identified by centrally located nuclei [26].
Based on this analysis, CHC22 mice exhibited delayed late-stage
muscle regeneration compared to WT mice (Table 1, Fig. 6). On
days 5 and 7, regenerating muscle fibers of WT mice and CHC22
mice were comparable in size as shown in H&E staining
(Figure 6A) and in their average cross-sectional area (Figure 6B)
or diameter (Table 1). However, on days 14 and 28 after
cardiotoxin injection, CHC22 mice had significantly smaller
regenerated muscle fibers in contrast to WT mice (Figure 6B,
Table 1). Especially on day 28, small regenerated muscle fibers
with central nuclei were more frequently observed in CHC22 mice
compared to WT mice (Figure 6A, shown by asterisks). The
GLUT4 response in the CHC22-mice is diminished but not
completely impaired [1]. This correlates with the modest degree of
reduction in muscle regeneration at late stages of recovery from
toxin injection, but still suggests that fiber maturation is affected by
disruption of GLUT4 traffic in these mice.
The presence of some smaller myofibers and some normal
myofibers in the CHC22 regenerating muscle, suggests that
regeneration of a subpopulation of myofibers is affected following
injury. To address this hypothesis, the fiber type composition of
muscle removed 28 days after injury was determined for WT and
CHC22-mice and the cross-sectional areas for each fiber type were
measured. Muscle sections were stained for NADH-TR, an
indicator of mitochondrial activity. From this procedure, oxidative
(red) myofibers stain darkly and glycolytic (white) myofibers stain
lightly, and intermediate fibers (pink) show intermediate coloration
(Figure 6C). In injured muscle of CHC22 mice (12 weeks of age),
the glycolytic fibers had a significantly smaller cross-sectional area
(Figure 6D), though fiber type composition was unchanged
(Figure 6E).
Myoblasts from CHC22-mice Fuse but do not Proliferate
in Response to Glucose
The delayed regeneration of glycolytic fibers in CHC22 mice
might be a direct effect of their impaired GLUT4-mediated
glucose uptake pathway. Oxidative fibers express more GLUT4
[38–40], so these fibers would potentially be less affected by the
over-sequestration of GLUT4 induced by the presence of CHC22.
To investigate whether the delay in regeneration observed in
CHC22 mice could be explained by GLUT4 pathway defects,
myoblasts isolated from CHC22 mice were compared to WT
myoblasts during growth in fusion media (FM), in which they form
differentiated myotubes (Figure 7). Isolated myoblasts from
CHC222 or WT mice were cultured in FM with either low
(5.6 mM) or high glucose (25 mM). After 24 h culture in either
glucose concentration, myoblasts from both CHC22-mice or WT
mice had started to fuse into small nascent myotubes with two to
three nuclei. By 48 h, larger mature myotubes with many nuclei
had formed in both CHC22 and WT cultures (Figure 7A and C).
After 24 h of culture in FM at either glucose concentration, about
35% of the CHC22 myonuclei were present in myotubes,
suggesting that the mechanics of fusion function properly in
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CHC22-mouse muscle (Figure 7B and D). In fact, compared to the
WT myoblasts, fusion of CHC22 myoblasts was increased under
either glucose condition, with a larger percentage of nuclei present
in myotubes. Enhanced fusion rate is a hallmark of myoblasts
under stress [41]. However, in contrast to the CHC22 myoblasts
and myotubes, the WT myoblasts continued to proliferate in
culture from 0–24 h, so that their overall numbers increased, while
the CHC22 myoblasts remained stable for 24 h and then their
numbers started to decline (Figure 7B and D). After 72 h of
culture, damaged myotubes were visible in the cultures from
CHC22-mice but were absent in cultures from WT mice
(arrowheads, Figure S2). WT myoblasts showed a greater increase
in numbers after 24 hours (total nuclei) when cultured in high
glucose (. twofold) compared to low glucose (, twofold)
(Figure 7B vs D). This increased proliferation in response to
increased glucose was not observed for the CHC22 myoblasts,
suggesting that impaired glucose uptake affects their proliferation,
and could account for delayed regeneration.
Fiber Type Switch during Aging of CHC22-mice
We observed fiber type differences in response to muscle injury
in CHC22-mice (Figure 6), suggesting that their poor myotube
survival and myoblast insensitivity to glucose (Figure 7) might
affect myofiber types differently. To address this, we examined the
fiber type composition of muscle from uninjured CHC22 mice
over time, using myosin isoforms as fiber type markers (Figure 8).
Oxidative fibers express type I myosin, while intermediate and
Figure 5. Elevation of components of the GLUT4 trafficking pathway during mouse skeletal muscle regeneration. A) VAMP2 and
CHC22 levels during muscle regeneration after cardiotoxin injection on day 0 were compared between WT and CHC22-mice in muscle samples
harvested on the day indicated. One typical set of immunoblots is shown at the left and quantification of VAMP2 relative to GAPDH signals from three
experiments generated the ratios plotted at the right (upper plot). There was a statistically significant difference between WT and CHC22-mice in
VAMP2 expression on day 14 after cardiotoxin injection (*p,0.05), as determined by Student’s t test. Quantification of VAMP2 and CHC22 relative to
GAPDH in the CHC22-mice shown at the left was plotted (right, bottom). B) GLUT4 levels during muscle regeneration for wild type and CHC22-mice
(n = 3). One typical set of immunoblots is shown at the left and quantification of GLUT4 relative to GAPDH signals is plotted on the right. No
significant difference between WT and CHC22-mice was detected. Molecular mass (kilodaltons) of the proteins detected is indicated at the right.
doi:10.1371/journal.pone.0077787.g005
Table 1. Mean diameter (microns) of regenerating muscle
fibers in wild type mice or CHC22 transgenic mice on
indicated days after cardiotoxin injection.
Control# Day 5 Day 7 Day 14 Day 28
WT
mice
mean 6
s.e.m.
71.160.5 31.260.2 38.060.2 53.060.5 71.060.4
n+ 1268 1164 1642 1799 2012
CHC22
mice
mean 6
s.e.m.
69.460.4 30.460.1 37.160.2 47.060.3** 63.660.4**
n 1308 1125 1669 1800 1988
#Control animals were not injected with cardiotoxin.
n+= total number of muscle fibers analyzed from 3 animals each of WT or
CHC22-mice.
**P,0.01, by Student’s t test.
doi:10.1371/journal.pone.0077787.t001
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Figure 6. Delayed maturation and fiber type analysis of regenerating fibers in CHC22-transgenic mice. A) Hematoxylin and eosin
staining of transverse muscle sections from WT or CHC22 transgenic mice after cardiotoxin injection at day 0, on the indicated days (D). Control
(CTRL) sections were prepared from uninjured muscle. On day 28, some CHC22 myofibers were similar in cross-sectional area and diameter to WT
myofibers; however, smaller myofibers (,40 mm diameter, marked by asterisks) were more frequently observed in the CHC22-mice compared to WT
mice (scale bar, 20 mm; n= 3). B) The mean cross-sectional area of myofibers with centrally located nuclei from WT (white bars) and CHC22-mice (black
bars) was calculated and plotted for each indicated day after cardiotoxin injection. Control mice for each strain were not injected with cardiotoxin.
There was a statistically significant difference in the average fiber cross-sectional area between WT mice and CHC22-mice on days 14 and 28 after
injection (n=3, evaluating 1200–2000 myofibers per mouse; **p,0.01), as determined by Student’s t test. C) Transverse sections of muscle from
CHC22-mice and WT mice, harvested 28 days after cardiotoxin injection, were stained for NADH-TR in order to determine the myofiber type.
Oxidative (red) myofibers appear dark, glycolytic (white) myofibers appear light and intermediate (pink) myofibers appear intermediate in color. D)
Fibers in 28-day regenerating muscle from CHC22-mice (black bars) and WT mice (white bars) were classified by type and their cross-sectional area
measured in pixels using ImageJ (n = 3, evaluating ,1500 fibers per mouse, *p,0.05, by Student’s t test). E) The percent of each fiber type in 28-day
regenerating muscle from CHC22-mice (black bars) and WT mice (white bars) from the analysis in D is plotted.
doi:10.1371/journal.pone.0077787.g006
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glycolytic fibers express type IIa and IIb myosins, respectively [37].
CHC22 mice that were twelve weeks or younger had myosin
expression similar to WT mice. However, aged CHC22-mice
(.24 weeks) had a decreased level of Type I myosin compared to
age-matched WT mice (Figure 8). A switch from oxidative to
glycolytic muscle is reported to occur in patients with type 2
diabetes [38], so this elevated glycolytic muscle phenotype for aged
CHC22-mice is consistent with their development of symptoms of
type 2 diabetes (hyperglycemia and sequestration of intracellular
GLUT4) by 20 weeks of age [1]. In younger CHC22-mice (12
weeks), the glycolytic fibers recovered from injury more slowly
than glycolytic fibers in WT mice of the same age (Figure 6), while
oxidative fibers showed no difference in response to injury. With
age, however, the survival of the oxidative fibers was decreased
(Figure 8). These phenotypes suggest that the impaired GLUT4
pathway of the CHC22-myoblasts leads to decreased growth rate
of the more glucose-dependent glycolytic fibers but also decreases
the long-term survival of the more robust oxidative fibers, which
are more insulin-dependent.
Discussion
Muscle growth and maturation depend on numerous factors,
including uptake of glucose through the glucose transporter
GLUT4 [42]. A role for GLUT4-mediated glucose uptake during
muscle regeneration has also been proposed [8]. Here we analyze
components of the GLUT4 membrane traffic pathway and their
expression in regenerating human muscle, as well as assess a role
Figure 7. Myoblasts from CHC22-mice undergo fusion but do not exhibit glucose-dependent proliferation. A and C) Images of primary
myoblasts from wild-type (WT) or CHC22-transgenic mice cultured in FM with A) low (5.6 mM) or C) high (25 mM) glucose for the indicated time in
hours (h), all seeded at the same density (scale bars, 100 mm). B and D) At the indicated time period for myoblasts cultured as in A and C, the nuclei
were quantified for total number (Total), number present in multi-nuclear myotubes (Myotube), and number in mono-nuclear cells (Myoblast). These
quantifications are plotted relative to the total nuclei present at the start of differentiation (switch to FM at 0 hours) for cultured myoblasts from
CHC22-mice (filled circles) and WT mice (open circles). Two-way ANOVA and Tukey-Kramer post-hoc test showed significant differences between WT
and CHC22 in all three panels. (*p,0.05 and **p,0.01) at indicated time points.
doi:10.1371/journal.pone.0077787.g007
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for the GLUT4 pathway in muscle regeneration in a transgenic
mouse model. We present evidence that membrane traffic of
GLUT4 is increasingly active during human and mouse muscle
regeneration and show that in CHC22-transgenic mice with
impaired GLUT4 membrane traffic in their skeletal muscle,
regeneration is delayed. The myoblasts from CHC22-mice do not
increase their proliferation in response to increased glucose, which
promotes proliferation of myoblasts from WT mice, suggesting a
connection between the impaired GLUT4 pathway in the
CHC22-transgenic animals and their impaired muscle regenera-
tion. The skeletal muscle of aged CHC22-mice also had an
increased percentage of glycolytic fibers, as seen in some patients
with type 2 diabetes [38]. Together these findings support a role
for GLUT4 function during muscle regeneration in humans and
mice and in maintenance of fiber type, at least in mice. In
addition, we show that markers of the GLUT4 pathway, including
GLUT4, CHC22 and VAMP2 are diagnostic for regenerating
human myofibers.
The GLUT4 transporter is sequestered in a GSC until it is
released in response to insulin stimulation, so its membrane traffic
is highly specialized. In humans, GSC formation in skeletal muscle
and adipocytes involves the CHC22 isoform of clathrin that is
missing from mice, defining a species-restricted aspect to GLUT4
membrane traffic [1]. Following up the demonstration that
CHC22 clathrin is a necessary component of the human GLUT4
pathway, we investigated whether the increased CHC22 levels,
previously observed in regenerating rat muscle [7], indicated
upregulation of the GLUT4 pathway during regeneration.
Analysis of regenerating muscle fibers in patients with four
different human myopathies revealed that levels of CHC22,
GLUT4 and VAMP2 are elevated during regeneration. These
proteins also have an altered internal distribution in regenerating
fibers compared to mature fibers in the same tissue, which can be
explained by repositioning of the nuclei and associated perinuclear
regions in regenerating muscle [26]. The elevation of GLUT4
pathway markers, combined with more visible staining of the GSC
region, suggests that active membrane traffic of GLUT4 and
regeneration of the GSC is occurring during human muscle
regeneration. High levels of CHC22 and GLUT4 in Pax7-positive
cells suggested that this pathway is amplified early in the
regenerative process.
The mechanism by which the GLUT4 pathway components
are stimulated is not clear. Earlier studies of rat muscle
regeneration revealed an interaction between the regulatory
GLUT4 enhancer sequence and transcription factors that are
induced during muscle regeneration [8], but the regulatory
sequences that affect CHC22 expression are not known. Here
we investigated whether signaling via inflammatory cytokines that
are present in regenerating muscle might influence expression of
CHC22 and we observed no effect of TNF-a, IL-1b or IFN-c on
expression of CHC22 in cultured human myotubes. Although
TNF-a was reported to influence GLUT4 expression in rat muscle
[29], no obvious effect was observed in cultured human myoblasts
and myotubes, nor did other cytokines affect GLUT4 expression
in these cultures. Thus, we suggest that inflammation is not
responsible for the observed increase in GLUT4 transport
components in regenerating human muscle and propose that the
increase results from some muscle-intrinsic program during
regeneration. The time course of GLUT4 pathway expansion in
regenerating mouse muscle coincides with the time course for
innervation (data not shown), suggesting that the pathway might
expand to meet the increased energy needs that accompany
contraction.
Figure 8. Muscle fiber type switch during aging of CHC22-mice. Skeletal muscle (gastrocnemius) was harvested from CHC22-mice and WT
mice at the indicated ages and tissue homogenate was analyzed by immunoblotting for Type I and Type IIa/b myosin heavy chains, as well as for
CHC22 and loading control GAPDH. A typical immunoblot for each age group is shown at the left. Signals for myosin heavy chain (MyHC) type levels
relative to GAPDH signals are shown at the right for 4–5 animals from the indicated age groups. The drop in Type I myosin heavy chain in aged
CHC22 mice is significant, *p,0.05, by Student’s t test.
doi:10.1371/journal.pone.0077787.g008
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We have previously demonstrated that transgenic mice
expressing CHC22 in their skeletal muscle and fat, under the
control of its human promoter, display clear defects in GLUT4
trafficking. In their skeletal muscle, presence of the CHC22
transgene causes excessive intracellular sequestration of GLUT4
and VAMP2 and a reduction of GLUT4 at the sarcolemma
and T-tubules. These changes are accompanied by age-
dependent hyperglycemia in the CHC22-mice [1]. With their
impairment of GLUT4 traffic and mild diabetic condition, the
CHC22-mice qualified as a model system to test the role of the
GLUT4 pathway in muscle regeneration. This approach was
validated by showing that CHC22 expression is increased upon
cardiotoxin injury of skeletal muscle in the CHC22-mice, and
that GLUT4 and VAMP2 levels increase in both WT and
CHC22-mice after injury, as predicted by our staining of
human regenerating muscle. Consistent with previously observed
trafficking defects in the GLUT4 pathway of the CHC22-mice
[1], the kinetics of VAMP2 expression in their muscle was
prolonged after injury compared to injured WT muscle.
Importantly, analysis of their skeletal muscle after cardiotoxin
injection revealed that the CHC22-mice have a delay in muscle
regeneration, characterized by a delay in myofiber maturation.
As CHC22, expressed in a tissue-specific fashion from its
endogenous human promoter, is not expressed in motor
neurons of the transgenic mice (data not shown), the defective
regeneration is most likely due to the presence of CHC22 in the
muscle fibers themselves and their associated defective GLUT4
traffic. Consistent with this interpretation, we observed that
isolated myoblasts from the CHC22-mice were capable of fusing
and forming myotubes, but did not proliferate in response to an
increase in glucose, as observed for myoblasts from WT mice.
Compared to WT myoblasts, the myoblasts from CHC22-mice
also had higher fusion rates, typical of myoblasts under stress
[41]. We therefore propose that the delayed maturation of
CHC22 myofibers during regeneration may be a consequence
of the defective GLUT4 pathway in the transgenic mice.
Not all of the regenerating fibers in the CHC22-mice were
diminished in size relative to the WT mice, so we compared the
fiber types in skeletal muscle of CHC22-mice with WT mice.
We found an increase in glycolytic fibers compared to oxidative
fibers in aged CHC22-mice, compared to age-matched WT
mice, which coincided with onset of hyperglycemia in the
former [1]. We also observed that in the injured muscle of
CHC22-mice, the glycolytic fibers had decreased cross-sectional
area compared to regenerating fibers in WT muscle. Since
glycolytic fibers have lower levels of GLUT4 [38–40] and are
more glucose-dependent, regeneration of the surviving glycolytic
fibers could be more sensitive to perturbation of the GLUT4
pathway, accounting for their reduced size compared to
regenerated oxidative fibers. Conversely, glycolytic fibers are
more reliant on GLUT1 than GLUT4 for glucose import, while
oxidative fibers are more dependent on GLUT4 [38–40]. Thus
over time, oxidative fibers may be less viable due to the
impairment of the insulin-responsive GLUT4 pathway that
occurs in CHC22 mice, resulting in the alteration of fiber type
composition we observed, which mimics that reported for type 2
diabetes. Hyperglycemia is characteristic of aged (.20 weeks
old) CHC22-mice [1], so the reduction of oxidative fibers
observed in aged CHC22-mice could also be a result of
secondary effects of their hyperglycemia. On the other hand,
the abnormality in muscle regeneration that we observed
following muscle injury of 8-week-old mice is feasibly a direct
cause of their impaired GLUT4 pathway rather than due to
long term diabetic symptoms. Though we did show defective
behavior of myoblasts from CHC22 mice in response to
glucose, there may be additional features of the impaired
GLUT4 pathway that influence muscle regeneration. For
example, the GLUT4 pathway also mobilizes the multi-
functional insulin-responsive amino peptidase (IRAP) [44].
Interestingly, the canonical transient receptor potential 3
(TRPC3), a non-selective cation channel, was shown to be
involved in insulin-responsive glucose uptake [45] and was also
implicated in muscle regeneration [46]. Establishing how the
GLUT4 pathway plays a role in muscle regeneration remains a
task for the future, but our combined studies of human tissue
and a mouse model in which the pathway is defective further
support that this pathway contributes to the regenerative
process.
Conclusions
In summary, this work defines a relationship between muscle
regeneration and the GLUT4 pathway for glucose metabolism.
Increased levels of GLUT4 pathway components are detected in
regenerating skeletal muscle fibers of humans and mice, as
predicted from earlier studies of rat skeletal muscle. In humans,
markers of this pathway include the species-restricted CHC22
isoform of clathrin, which can now be considered a marker of
muscle regeneration. Furthermore, we demonstrate a functional
role for the GLUT4 pathway in glucose-dependent myoblast
proliferation and a negative impact on muscle regeneration when
this pathway is impaired. Impairment of the GLUT4 pathway also
correlated with long-term changes in muscle fiber type. Together
these observations may explain aspects of muscle wasting in
patients with insulin-resistant type 2 diabetes [43] and define the
GLUT4 pathway as a potential target to stimulate muscle
regeneration.
Supporting Information
Figure S1 Evidence of regeneration in samples from
patients with dermatomyositis and necrotizing myopa-
thy. (A) Hemotoxylin and eosin (H&E) staining shows numerous
regenerating fibers in samples from DM and NM patients,
characterized by large nuclei with a non-peripheral location.
Examples of regenerating fibers are indicated by black arrow-
heads. (B) Samples from both patients were double-labeled with
antibodies against CHC22 and GLUT4, detected by distinct
fluorophores, as in Figure 2A. Regenerating fibers that stain for
both markers are indicated by white arrowheads.
(TIF)
Figure S2 Damaged myotubes in 72 h cultures of
myoblasts from CHC22-mice. Images of primary myoblasts
from WT and CHC22-mice cultured 72 h in FM with low
(5.6 mM) or high (25 mM) glucose. Regions 1 and 2 are magnified
below. White arrowheads indicate cauliflower-like damaged
myotubes visible in the cultures from CHC22-mice (scale bars,
100 mm).
(TIF)
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